



## **FROST & SULLIVAN SELECTS PROPRIETARY TECHNOLOGY PLATFORM AS U.S. STEM CELL MARKET INNOVATION OF THE YEAR**

**New York, NY; 14 November 2008:** Angioblast Systems Inc., announced today that its adult stem cell technology platform has been awarded the 2008 Frost & Sullivan United States Stem Cell Market Technology Innovation of the Year.

This Award recognizes Angioblast Systems Inc., for its success in developing and introducing new/disruptive technology, formulating a well-designed product family, and making significant technology contributions to the industry. The selection of this award is based on interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team. The Award is made to the company that received the number one industry rank.

According to Frost and Sullivan industry analyst Katheryn Symank, "Angioblast's proprietary technology has several attractive attributes that set it apart from other stem cell products, including very accurate identification and isolation. This technology allows for a cell population with up to 1000-fold greater concentration of stem cells compared to other conventional sorting methods. Moreover, due to the non-immunogenic nature of the cells, Angioblast's highly concentrated and pure population of stem cells can provide a well-regulated, consistent batched product with stringent release criteria akin to small molecule pharmaceuticals."

"Since Angioblast's proprietary technology allows for a very pure, potent and homogenous cell population, we view the recent pharmaceutical partnering activity in the stem cell space as a major validation of Angioblast's approach. This underscores the company's prospects for significant commercial transactions," Symank noted.

"We are honored to be recognized with this prestigious award from Frost & Sullivan," said Company Founder, Professor Silviu Itescu.

"We will continue to optimize and progress our innovative technology in order to produce novel therapies for major cardiac, vascular, eye and orthopedic indications with unmet clinical needs," he added.

### **About Frost & Sullivan**

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit <http://www.frost.com>.

## **About Angioblast Systems, Inc.**

Angioblast Systems, Inc. is a private New York City based biotechnology company committed to the development of novel treatments for cardiac, vascular, and eye conditions. Angioblast's lead products are based on commercialization of a unique adult stem cell technology capable of regulating blood vessel growth critical for the treatment of ischemic heart disease and macular degeneration/diabetic eye disease. Our focus is to progress through clinical trials and regulatory processes necessary to commercialize the technology in as short a timeframe as possible. Angioblast has the worldwide assignment of rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction, culture expansion and enablement of adult Mesenchymal Precursor Cells (MPCs). Angioblast's strategy is to maximize shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.

*For further information please contact*

Michael Schuster, MS, MBA  
Vice President of Operations  
T: (212) 880-2060  
E: [michael.schuster@angioblast.com](mailto:michael.schuster@angioblast.com)  
W: [www.angioblast.com](http://www.angioblast.com)